Companies Sage Therapeutics
Sage Therapeutics (SAGE): executive pay, fiscal 2024
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Sage Therapeutics’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers20th pct.Of 40 peer CEOs
CEO pay, last three years
- $5,705,164FY2022
- $6,237,491FY2023
- $7,112,589FY2024
CEO total pay was $7,112,589 in fiscal 2024, up from $6,237,491 in fiscal 2023.
FY2024: salary $830,712 · bonus $0 · stock awards $3,164,364 · option awards $2,669,263
Executives and directors
Barry Greene · CEOAnne Marie Cook · General CounselKimi Iguchi · CFOLaura Gault · Chief Medical OfficerElizabeth Barrett · Independent DirectorGeno Germano · Independent DirectorGeorge Golumbeski · Independent DirectorJames M. Frates · Independent DirectorJeffrey M. Jonas · Independent DirectorJessica Federer · Independent DirectorKevin P. Starr · Independent DirectorMichael F. Cola · Independent DirectorSteven Paul · Independent Director
Frequently asked questions
Who was the highest-paid executive at Sage Therapeutics in fiscal 2024?
As disclosed, Barry Greene (Chief Executive Officer and President) was the highest-paid executive at Sage Therapeutics in fiscal 2024, with total compensation of $7,112,589.
How does Sage Therapeutics's chief executive pay compare to its disclosed peer group?
As disclosed, Barry Greene's total compensation ranked at the 20th percentile of Sage Therapeutics's disclosed peer group.
What is Sage Therapeutics's CEO-to-median employee pay ratio?
As disclosed, Sage Therapeutics's CEO-to-median employee pay ratio was 19:1.
How did shareholders vote on Sage Therapeutics's executive compensation?
As disclosed, 76.72% of shareholders supported Sage Therapeutics's executive compensation in the latest say-on-pay vote.
How much does Sage Therapeutics spend in total on board compensation for fiscal 2024?
As disclosed, Sage Therapeutics reported total board compensation of $562,594 for fiscal 2024.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Barry Greene | $830,712 | $0 | $3,164,364 | $2,669,263 | $431,970 | $0 | $16,280 | $7,112,589 |
| Chief Executive Officer and President | ||||||||
| Kimi Iguchi | 421,260 | 0 | 1,542,448 | 361,447 | 0 | 0 | 742,520 | 3,067,675 |
| Former Chief Financial Officer and Treasurer | ||||||||
| Christopher Benecchi | 532,236 | 40,000 | 1,365,700 | 481,488 | 179,200 | 0 | 6,364 | 2,604,988 |
| Chief Operating Officer and Treasurer | ||||||||
| Anne Marie Cook | 430,329 | 0 | 1,106,573 | 359,373 | 0 | 0 | 685,435 | 2,581,710 |
| Former Senior Vice President, General Counsel and Secretary | ||||||||
| Laura Gault | 550,174 | 0 | 1,106,573 | 357,531 | 176,056 | 0 | 12,719 | 2,203,053 |
| Former Chief Medical Officer | ||||||||
| Gregory Shiferman | 435,467 | 20,000 | 99,310 | 453,013 | 152,000 | 0 | 9,878 | 1,169,668 |
| Senior Vice President, General Counsel and Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Barry Greene | $7,112,589 | $6,237,491 | $5,705,164 | ↑ +875,098 |
| Kimi Iguchi | 3,067,675 | 1,984,101 | 1,624,967 | ↑ +1,083,574 |
| Christopher Benecchi | 2,604,988 | 2,280,917 | 1,865,704 | ↑ +324,071 |
| Anne Marie Cook | 2,581,710 | 2,150,623 | 1,671,197 | ↑ +431,087 |
| Laura Gault | 2,203,053 | 1,274,325 | 3,967,795 | ↑ +928,728 |
| Gregory Shiferman | 1,169,668 | 1,318,968 | 686,376 | ↓ −149,300 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company maintains a strong pay-for-performance orientation by making a significant portion of total compensation variable and dependent on performance against goals, differentiating awards based on individual performance, and tying the vesting of certain PSU awards to specified TSR milestones to align executive interests with stockholder return.
| CEO STI target (% of salary) | 150% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2024
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Senior Vice | PSU | 2024-02-13 | — | 3,000 | — | 3,000 | $69,060 |
| Christopher Benecchi | OPTION | 2024-02-13 | — | — | 27,000 | — | 429,022 |
| Christopher Benecchi | PSU | 2024-02-13 | — | 13,500 | — | 13,500 | 310,770 |
| Christopher Benecchi | PSU | 2024-02-13 | — | 8,100 | — | 16,200 | 271,269 |
| Christopher Benecchi | OPTION | 2024-11-01 | — | — | 12,500 | — | 52,466 |
| Anne Marie Cook | OPTION | 2020-04-28 | — | — | 9,450 | — | 1,351,350 |
| Anne Marie Cook | PSU | 2024-02-13 | — | 6,750 | — | 13,500 | 226,058 |
| Anne Marie Cook | OPTION | 2022-02-11 | — | — | 10,133 | — | 1,134,896 |
| Anne Marie Cook | OPTION | 2015-09-16 | — | — | 109,300 | — | 41,096,800 |
| Anne Marie Cook | PSU | 2024-02-13 | — | 27,000 | — | 27,000 | 621,540 |
| Laura Gault | PSU | 2024-02-13 | — | 6,750 | — | 13,500 | 226,058 |
| Laura Gault | OPTION | 2024-02-13 | — | — | 22,500 | — | 357,531 |
| Barry Greene | PSU | 2024-02-13 | — | 25,200 | — | 50,400 | 843,948 |
| Gregory Shiferman | OPTION | 2024-02-21 | — | — | 20,608 | — | 314,942 |
| Senior Vice | OPTION | 2024-02-13 | — | — | 6,000 | — | 95,345 |
| Christopher Benecchi | PSU | 2024-11-01 | — | 6,250 | — | 6,250 | 37,813 |
| Anne Marie Cook | PSU | 2024-02-13 | — | 11,250 | — | 11,250 | 258,975 |
| Gregory Shiferman | PSU | 2024-02-13 | — | 3,000 | — | 3,000 | 69,060 |
| Christopher Benecchi | PSU | 2024-02-13 | — | 32,400 | — | 32,400 | 745,848 |
| Senior Vice | OPTION | 2024-02-21 | — | — | 20,608 | — | 314,942 |
| Laura Gault | PSU | 2024-02-13 | — | 27,000 | — | 27,000 | 621,540 |
| Laura Gault | PSU | 2024-02-13 | — | 11,250 | — | 11,250 | 258,975 |
| Barry Greene | PSU | 2024-02-13 | — | 100,800 | — | 100,800 | 2,320,416 |
| Kimi Iguchi | PSU | 2024-02-13 | — | 27,000 | — | 27,000 | 703,620 |
| Gregory Shiferman | PSU | 2024-11-01 | — | 5,000 | — | 5,000 | 30,250 |
| Anne Marie Cook | OPTION | 2017-02-06 | — | — | 46,480 | — | 15,477,840 |
| Barry Greene | OPTION | 2024-02-13 | — | — | 168,000 | — | 2,669,263 |
| Gregory Shiferman | OPTION | 2024-11-01 | — | — | 10,000 | — | 42,726 |
| Anne Marie Cook | OPTION | 2021-02-10 | — | — | 17,417 | — | 156,753 |
| Anne Marie Cook | OPTION | 2016-02-08 | — | — | 15,000 | — | 11,655,000 |
| Anne Marie Cook | OPTION | 2023-02-13 | — | — | 7,917 | — | 562,107 |
| Anne Marie Cook | OPTION | 2024-02-13 | — | — | 22,500 | — | 357,526 |
| Anne Marie Cook | OPTION | 2020-02-12 | — | — | 20,000 | — | 520,000 |
| Gregory Shiferman | OPTION | 2024-02-13 | — | — | 6,000 | — | 95,345 |
| Anne Marie Cook | OPTION | 2019-02-13 | — | — | 19,000 | — | — |
| Anne Marie Cook | OPTION | 2018-04-02 | — | — | 15,750 | — | — |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Senior Vice | $0 | $69,060 | $410,287 | 14.4% |
| Christopher Benecchi | 0 | 1,365,700 | 481,488 | 73.9% |
| Anne Marie Cook | 0 | 1,106,573 | 72,312,272 | 1.5% |
| Laura Gault | 0 | 1,106,573 | 357,531 | 75.6% |
| Barry Greene | 0 | 3,164,364 | 2,669,263 | 54.2% |
| Gregory Shiferman | 0 | 99,310 | 453,013 | 18.0% |
| Kimi Iguchi | 0 | 703,620 | 0 | 100.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Gregory Shiferman | PSU | 704 | — | $3,823 |
| Kimi Iguchi | Option | 792 | 82.27 | — |
| Laura Gault | Option | 1,441 | 45.28 | — |
| Gregory Shiferman | PSU | 1,500 | — | 8,145 |
| Gregory Shiferman | PSU | 2,163 | — | 11,745 |
| Laura Gault | PSU | 2,170 | — | 11,783 |
| Gregory Shiferman | PSU | 3,000 | — | 16,290 |
| Christopher Benecchi | Option | 3,325 | 43.04 | — |
| Gregory Shiferman | PSU | 3,375 | — | 18,326 |
| Christopher Benecchi | Option | 3,562 | 31.36 | — |
| Gregory Shiferman | PSU | 4,125 | — | 22,399 |
| Kimi Iguchi | Option | 4,433 | 43.04 | — |
| Gregory Shiferman | PSU | 5,000 | — | 27,150 |
| Gregory Shiferman | Option | 6,000 | 23.02 | — |
| Christopher Benecchi | PSU | 6,250 | — | 33,938 |
| Kimi Iguchi | PSU | 6,650 | — | 36,110 |
| Laura Gault | PSU | 6,750 | — | 36,653 |
| Kimi Iguchi | PSU | 6,750 | — | 36,653 |
| Christopher Benecchi | PSU | 7,500 | — | 40,725 |
| Gregory Shiferman | PSU | 7,500 | — | 40,725 |
| Laura Gault | PSU | 7,500 | — | 40,725 |
| Kimi Iguchi | PSU | 7,500 | — | 40,725 |
| Christopher Benecchi | PSU | 7,750 | — | 42,083 |
| Christopher Benecchi | PSU | 8,100 | — | 43,983 |
| Christopher Benecchi | Option | 8,437 | 45.29 | — |
| Kimi Iguchi | Option | 9,057 | 45.28 | — |
| Gregory Shiferman | Option | 9,159 | 22.2 | — |
| Christopher Benecchi | PSU | 9,300 | — | 50,499 |
| Gregory Shiferman | Option | 10,000 | 6.05 | — |
| Laura Gault | PSU | 11,250 | — | 61,088 |
| Kimi Iguchi | PSU | 11,250 | — | 61,088 |
| Christopher Benecchi | Option | 11,321 | 45.28 | — |
| Kimi Iguchi | PSU | 12,400 | — | 67,332 |
| Christopher Benecchi | Option | 12,500 | 6.05 | — |
| Christopher Benecchi | PSU | 13,500 | — | 73,305 |
| Laura Gault | PSU | 13,500 | — | 73,305 |
| Kimi Iguchi | PSU | 13,500 | — | 73,305 |
| Kimi Iguchi | PSU | 13,640 | — | 74,065 |
| Christopher Benecchi | PSU | 15,750 | — | 85,523 |
| Christopher Benecchi | PSU | 16,200 | — | 87,966 |
| Christopher Benecchi | PSU | 17,050 | — | 92,582 |
| Barry Greene | PSU | 20,000 | — | 108,600 |
| Barry Greene | Option | 20,393 | 43.04 | — |
| Laura Gault | Option | 22,500 | 23.02 | — |
| Kimi Iguchi | Option | 22,500 | 23.02 | — |
| Barry Greene | PSU | 25,200 | — | 136,836 |
| Christopher Benecchi | Option | 27,000 | 23.02 | — |
| Laura Gault | Option | 29,521 | 37.88 | — |
| Barry Greene | Option | 36,021 | 45.28 | — |
| Barry Greene | PSU | 50,400 | — | 273,672 |
| Laura Gault | PSU | 52,545 | — | 285,319 |
| Barry Greene | PSU | 54,250 | — | 294,578 |
| Barry Greene | PSU | 57,040 | — | 309,727 |
| Barry Greene | Option | 168,000 | 23.02 | — |
| Barry Greene | Option | 455,000 | 85.82 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Jeffrey M. JonasIndependent · Departed during FY | $59,643 | — | $91,810 | — | $40,000 | $191,453 |
| Geno GermanoIndependent · Board Chair · Nominating and Corporate Governance (Chair) | 98,682 | — | 91,810 | — | 0 | 190,492 |
| James M. FratesIndependent · Audit (Chair) · Compensation | 77,500 | — | 91,810 | — | 0 | 169,310 |
| Michael F. ColaIndependent · Compensation (Chair) · Nominating and Corporate Governance | 75,410 | — | 91,810 | — | 0 | 167,220 |
| Elizabeth BarrettIndependent · Audit · Compensation | 67,500 | — | 91,810 | — | 0 | 159,310 |
| Jessica FedererIndependent · Audit | 59,863 | — | 91,810 | — | 0 | 151,673 |
| George GolumbeskiIndependent · Nominating and Corporate Governance | 55,000 | — | 91,810 | — | 0 | 146,810 |
| Steven PaulIndependent · Departed during FY | 27,835 | — | 0 | — | 0 | 27,835 |
| Kevin P. StarrIndependent · Departed during FY | 1,161 | — | 0 | — | 0 | 1,161 |
Board fee structure and ownership guideline
| Annual cash retainer | — |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | — |
| Stock ownership guideline | stock ownership guidelines for our executives and non-employee directors, and a clawback policy to recover cash and equity incentive awards |
Total cost of the board
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $522,594 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $40,000 |
| Total cost of the board | $562,594 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Sage Therapeutics as a peer
Companies that benchmark against SAGE
14 companies name SAGE as a compensation peer
The list of companies that name SAGE as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2024
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
TVTX Travere TherapeuticsAGIO Agios Pharmaceuticals, Inc.CRSP CRISPR Therapeutics, Inc.AMLX Amylyx PharmaceuticalsALEC Alector, Inc.HALO Halozyme Therapeutics, Inc.FOLD Amicus Therapeutics, Inc.INSM Insmed, Inc.APLS Apellis Pharmaceuticals, Inc.AXSM Axsome Therapeutics, Inc.BPMC Blueprint Medicines CorporationSUPN Supernus Pharmaceuticals, Inc.RARE Ultragenyx Pharmaceutical Inc.EXEL Exelixis, Inc.ARDX ArdelyxDVAX Dynavax TechnologiesESPR Esperion TherapeuticsIRWD Ironwood PharmaceuticalsTARS Tarsus PharmaceuticalsRYTM Rhythm Pharmaceuticals, Inc.HRMY Harmony Biosciences Holdings, Inc. FibroGen, Inc.ACAD ACADIA Pharmaceuticals Inc.BCRX BioCryst PharmaceuticalsCERE Cerevel Therapeutics, Inc.DCPH Deciphera Pharmaceuticals, Inc.ITCI Intra-Cellular Therapies, Inc.MRTX Mirati Therapeutics, Inc. WeightPFGC PerformanceACAD ACADIA Pharmaceuticals Inc.CRSP CRISPR Therapeutics, Inc.AGIO Agios Pharmaceuticals, Inc.DCPH Deciphera Pharmaceuticals, Inc.ALKT Alector, Inc.HALO Halozyme Therapeutics, Inc.FOLD Amicus Therapeutics, Inc.HMY Harmony Biosciences Holdings, Inc.AMLX Amylyx PharmaceuticalsINSM Insmed, Inc.
Peer reciprocity
The companies Sage Therapeutics names as compensation peers that name it back in their own disclosed peer groups.
Agios Pharmaceuticals, Inc. (AGIO)123Harmony Biosciences Holdings, Inc. (HRMY)124ACADIA Pharmaceuticals Inc. (ACAD)125Cerevel Therapeutics, Inc. (CERE)126Intra-Cellular Therapies, Inc. (ITCI)127
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exelixis, Inc. | 2025 | Michael Morrissey | $1,306,040 | $30,539,552 | $0 | $1,382,591 | $33,239,183 |
| 2 | Halozyme Therapeutics, Inc. | 2025 | Helen Torley | 1,000,000 | 19,350,145 | 1,650,014 | 1,147,500 | 23,166,223 |
| 3 | Rhythm Pharmaceuticals, Inc. | 2025 | David Meeker | 807,692 | 8,274,785 | 7,688,560 | 759,488 | 17,544,525 |
| 4 | Supernus Pharmaceuticals, Inc. | 2025 | Jack Khattar | 1,036,000 | 6,535,029 | 7,031,545 | 846,930 | 15,501,557 |
| 5 | Insmed, Inc. | 2025 | William Lewis | 854,550 | 2,999,940 | 9,000,033 | 1,495,463 | 14,467,393 |
| 6 | Blueprint Medicines Corporation | 2024 | Kathryn Haviland | 821,363 | 7,472,480 | 4,315,144 | 854,217 | 13,477,004 |
| 7 | BioCryst Pharmaceuticals | 2025 | Jon Stonehouse | 728,466 | 0 | 11,132,458 | 1,052,633 | 12,951,082 |
| 8 | Mirati Therapeutics, Inc. | 2022 | David Meek | 749,423 | 6,043,885 | 4,233,427 | 438,985 | 11,937,371 |
| 9 | Ultragenyx Pharmaceutical Inc. | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 10 | Cerevel Therapeutics, Inc. | 2022 | N. Anthony Coles | 642,735 | 0 | 10,085,985 | 496,706 | 11,225,426 |
| 11 | Apellis Pharmaceuticals, Inc. | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 12 | Axsome Therapeutics, Inc. | 2025 | Herriot Tabuteau | 835,000 | 5,533,554 | 2,833,237 | 876,750 | 10,283,492 |
| 13 | Intra-Cellular Therapies, Inc. | 2023 | Sharon Mates | 891,653 | 7,749,984 | 0 | 0 | 10,086,413 |
| 14 | Amicus Therapeutics, Inc. | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 15 | Travere Therapeutics | 2025 | Eric Dube | 854,250 | 3,314,520 | 3,309,384 | 964,125 | 8,457,151 |
| 16 | Acadia Pharmaceuticals Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 17 | Dynavax Technologies | 2024 | Ryan Spencer | 835,001 | 4,902,150 | 1,824,299 | 641,907 | 8,210,775 |
| 18 | Harmony Biosciences Holdings, Inc. | 2025 | Jeffrey Dayno | 743,600 | 1,976,520 | 4,599,000 | 558,000 | 7,899,535 |
| 19 | Ardelyx | 2025 | Michael Raab | 797,000 | 2,953,724 | 3,413,948 | 627,638 | 7,796,171 |
| 20 | Crispr Therapeutics, Inc. | 2025 | Samarth Kulkarni | 768,622 | 3,474,900 | 2,768,862 | 659,093 | 7,678,477 |
| 21 | Alector, Inc. | 2025 | Alex Shootman | 558,480 | 6,222,675 | 0 | 699,775 | 7,492,018 |
| 22 | Performance | 2026 | Scott McPherson | 880,385 | 4,250,191 | 0 | 1,933,218 | 7,129,941 |
| 23 | Sage Therapeutics | 2024 | Barry Greene | 830,712 | 3,164,364 | 2,669,263 | 431,970 | 7,112,589 |
| 24 | Tarsus Pharmaceuticals | 2025 | Bobak Azamian | 726,333 | 2,648,284 | 2,651,487 | 555,700 | 6,617,979 |
| 25 | Deciphera Pharmaceuticals, Inc. | 2023 | Steven Hoerter | 738,200 | 1,935,000 | 2,837,100 | 487,212 | 6,010,712 |
| 26 | Agios Pharmaceuticals, Inc. | 2025 | Brian Goff | 846,864 | 1,291,680 | 2,627,252 | 592,804 | 5,370,389 |
| 27 | Esperion Therapeutics | 2025 | Sheldon Koenig | 770,833 | 1,260,000 | 847,929 | 639,375 | 3,535,512 |
| 28 | Amylyx Pharmaceuticals | 2025 | Justin Klee | 686,200 | 650,226 | 817,783 | 548,098 | 2,719,807 |
| 29 | Alector, Inc. | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| 30 | Ironwood Pharmaceuticals | 2025 | Thomas McCourt | 867,568 | 411,696 | 0 | 650,676 | 1,948,390 |
| — | Harmony Biosciences Holdings, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Sage Therapeutics | 80% | not disclosed | Yes — TSR milestones / Relative TSR vs. Nasdaq Biotechnology Index | Alpine Rewards |
| Acadia Pharmaceuticals Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Agios Pharmaceuticals, Inc. | 100% | Option 40 · PSU 40 · RSU 20 | No | Aon |
| Alector, Inc. | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Alector, Inc. | 125.3% | RSU 100 | not disclosed | FW Cook |
| Amicus Therapeutics, Inc. | not disclosed | Option 33 · RSU 33 · PRSU 33 | Yes — TSR Goal | Pay Governance |
| Amylyx Pharmaceuticals | 106.5% | not disclosed | No | Pearl Meyer |
| Apellis Pharmaceuticals, Inc. | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| Ardelyx | 105% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| Axsome Therapeutics, Inc. | 150% | RSU 33 · Options 33 · PSU 33 | No | Frederic W. Cook & Co., Inc. |
| BioCryst Pharmaceuticals | not disclosed | not disclosed | not disclosed | Aon |
| Blueprint Medicines Corporation | 130% | RSU 37 · Options 32 · PSU 31 | Yes — Relative Total Stockholder Return (rTSR) | Aon |
| Cerevel Therapeutics, Inc. | 128.8% | Options 100 | not disclosed | Pay Governance LLC |
| Crispr Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| Deciphera Pharmaceuticals, Inc. | 110% | Option 50 · PSU 50 · RSU 25 | No | Pearl Meyer & Partners, LLC |
| Dynavax Technologies | 102.5% | Options 34 · RSU 33 · PSU 33 | Yes — Relative Total Stockholder Return (rTSR) ranking vs. Nasdaq Biotechnology Index | Alpine |
| Esperion Therapeutics | 110% | not disclosed | not disclosed | not disclosed |
| Exelixis, Inc. | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| Halozyme Therapeutics, Inc. | 127.5% | PSU 50 · RSU 35 · Option 15 | No | F.W. Cook & Co., Inc. |
| Harmony Biosciences Holdings, Inc. | 100% | not disclosed | not disclosed | Pay Governance |
| Harmony Biosciences Holdings, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Insmed, Inc. | 175% | Options 75 · RSU 25 | No | Willis Towers Watson (WTW) |
| Intra-Cellular Therapies, Inc. | not disclosed | RSU 75 · PRSU 25 | Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology Index | Aon Consulting, Inc. |
| Ironwood Pharmaceuticals | 100% | RSU 50 · PSU 50 | not disclosed | Alpine Rewards LLC |
| Mirati Therapeutics, Inc. | not disclosed | Option 50 · RSU 50 | not disclosed | Aon Human Capital Solutions and Alpine Rewards |
| Performance | 150.4% | PSU 60 · RSU 40 | Yes — Relative TSR | Meridian Compensation Partners, LLC |
| Rhythm Pharmaceuticals, Inc. | 120% | Options 50 · RSU 50 | No | Pay Governance |
| Supernus Pharmaceuticals, Inc. | not disclosed | not disclosed | No | Aon |
| Tarsus Pharmaceuticals | 108% | Options 50 · RSU 50 | No | Pay Governance |
| Travere Therapeutics | 150% | not disclosed | No | Aon |
| Ultragenyx Pharmaceutical Inc. | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-04-16 | 35,986,261 | 10,918,957 | 348,822 | 76.72% | Passed |
| 2024 | 2024-04-16 | 47,705,636 | 2,299,792 | 41,352 | 95.4% | Passed |
| 2023 | 2023-04-17 | 39,995,146 | 11,173,607 | 39,894 | 78.16% | Passed |
| 2021 | 2021-06-10 | 33,691,544 | 16,696,177 | 12,333 | 66.86% | Passed |
| 2020 | 2020-06-09 | 26,623,925 | 16,643,658 | 17,523 | 61.53% | Passed |
| 2019 | 2019-06-05 | 44,332,822 | 680,835 | 8,943 | 98.49% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-04-16 | 76.72%a |
| 2024 | 2024-04-16 | 95.4%b |
| 2023 | 2023-04-17 | 78.16%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 19 : 1 |
|---|---|
| CEO total compensation | $6,237,491 |
| Median employee compensation | $337,122 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Elizabeth Barrett | Director | 2025-06-11 | A | 21,500 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Michael F. Cola | Director | 2025-06-11 | A | 21,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jessica Federer | Director | 2025-06-11 | A | 21,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| George Golumbeski | Director | 2025-06-11 | A | 21,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James M. Frates | Director | 2025-06-11 | A | 21,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Geno Germano | Director | 2025-06-11 | A | 21,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregory Shiferman | See Remarks | 2025-06-24 | D | 79 | 9 | 728 | Common | Form 4 ↗ |
| Michael C. Quirk | See Remarks | 2025-06-24 | D | 113 | 9 | 1,042 | Common | Form 4 ↗ |
| Barry Greene | Director | 2025-07-31 | D | 46,940 | — | — | Common | Form 4 ↗ |
| James M. Frates | Director | 2025-07-31 | D | 2,845 | — | — | Common | Form 4 ↗ |
| George Golumbeski | Director | 2025-07-31 | D | 13,593 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James M. Frates | Director | 2025-07-31 | D | 21,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael C. Quirk | See Remarks | 2025-07-31 | D | 4,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gregory Shiferman | See Remarks | 2025-07-31 | D | 7,215 | — | — | Common | Form 4 ↗ |
| Barry Greene | Director | 2025-07-31 | D | 174,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gregory Shiferman | See Remarks | 2025-07-31 | D | 10,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gregory Shiferman | See Remarks | 2025-07-31 | D | 23,735 | — | — | Common | Form 4 ↗ |
| James M. Frates | Director | 2025-07-31 | D | 19,154 | — | — | Derivative, Class A Common | Form 4 ↗ |
| George Golumbeski | Director | 2025-07-31 | D | 21,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| George Golumbeski | Director | 2025-07-31 | D | 8,000 | — | — | Common | Form 4 ↗ |
| Elizabeth Barrett | Director | 2025-07-31 | D | 3,000 | — | — | Common | Form 4 ↗ |
| Michael F. Cola | Director | 2025-07-31 | D | 21,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christopher Benecchi | Chief Operating Officer | 2025-07-31 | D | 40,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christopher Benecchi | Chief Operating Officer | 2025-07-31 | D | 36,375 | — | — | Common | Form 4 ↗ |
| Christopher Benecchi | Chief Operating Officer | 2025-07-31 | D | 28,053 | — | — | Common | Form 4 ↗ |
| Jessica Federer | Director | 2025-07-31 | D | 21,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael C. Quirk | See Remarks | 2025-07-31 | D | 36,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael C. Quirk | See Remarks | 2025-07-31 | D | 7,962 | — | — | Common | Form 4 ↗ |
| Michael C. Quirk | See Remarks | 2025-07-31 | D | 24,999 | — | — | Common | Form 4 ↗ |
| Christopher Benecchi | Chief Operating Officer | 2025-07-31 | D | 12,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Barry Greene | Director | 2025-07-31 | D | 53,229 | — | — | Common | Form 4 ↗ |
| Elizabeth Barrett | Director | 2025-07-31 | D | 21,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Geno Germano | Director | 2025-07-31 | D | 21,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Gregory Shiferman | See Remarks | 2025-07-31 | D | 28,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (127 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Barry Greene. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · page 48. As printed: 7,112,589. View filing ↗
- Section 01, Kimi Iguchi. DEF 14A, filed 2025-04-24. Section “Executive Compensation”. As printed: 3,067,675. View filing ↗
- Section 01, Christopher Benecchi. DEF 14A, filed 2025-04-24. Section “Executive Compensation”. As printed: 2,604,988. View filing ↗
- Section 01, Anne Marie Cook. DEF 14A, filed 2025-04-24. Section “Executive Compensation”. As printed: 2,581,710. View filing ↗
- Section 01, Laura Gault. DEF 14A, filed 2025-04-24. Section “Executive Compensation”. As printed: 2,203,053. View filing ↗
- Section 01, Gregory Shiferman. DEF 14A, filed 2025-04-24. Section “Executive Compensation”. As printed: 1,169,668. View filing ↗
- Section 03, Senior Vice PSU. DEF 14A, filed 2025-04-24. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Christopher Benecchi OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Christopher Benecchi PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Christopher Benecchi PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Christopher Benecchi OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Anne Marie Cook OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Anne Marie Cook PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Anne Marie Cook OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Anne Marie Cook OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Anne Marie Cook PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Laura Gault PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Laura Gault OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Barry Greene PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Gregory Shiferman OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Senior Vice OPTION. DEF 14A, filed 2025-04-24. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Christopher Benecchi PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Anne Marie Cook PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Gregory Shiferman PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Christopher Benecchi PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Senior Vice OPTION. DEF 14A, filed 2025-04-24. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Laura Gault PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Laura Gault PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Barry Greene PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Kimi Iguchi PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Gregory Shiferman PSU. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Anne Marie Cook OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Barry Greene OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Gregory Shiferman OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Anne Marie Cook OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Anne Marie Cook OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Anne Marie Cook OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Anne Marie Cook OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Anne Marie Cook OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Gregory Shiferman OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Anne Marie Cook OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Anne Marie Cook OPTION. DEF 14A, filed 2025-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2024-04-24. Section “CEO Pay Ratio”. As printed: 19 : 1. View filing ↗
- Section 08, Jeffrey M. Jonas. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 191,453. View filing ↗
- Section 08, Geno Germano. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 190,492. View filing ↗
- Section 08, James M. Frates. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 169,310. View filing ↗
- Section 08, Michael F. Cola. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 167,220. View filing ↗
- Section 08, Elizabeth Barrett. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 159,310. View filing ↗
- Section 08, Jessica Federer. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 151,673. View filing ↗
- Section 08, George Golumbeski. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 146,810. View filing ↗
- Section 08, Steven Paul. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 27,835. View filing ↗
- Section 08, Kevin P. Starr. DEF 14A, filed 2025-04-24. Section “Director Compensation”. As printed: 1,161. View filing ↗
- Section 02, Elizabeth Barrett 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael F. Cola 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jessica Federer 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, George Golumbeski 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James M. Frates 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geno Germano 2025-06-11. Form 4, filed 2025-06-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregory Shiferman 2025-06-24. Form 4, filed 2025-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael C. Quirk 2025-06-24. Form 4, filed 2025-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Barry Greene 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James M. Frates 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, George Golumbeski 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James M. Frates 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael C. Quirk 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregory Shiferman 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Barry Greene 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregory Shiferman 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregory Shiferman 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James M. Frates 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, George Golumbeski 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, George Golumbeski 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Barrett 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael F. Cola 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Benecchi 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Benecchi 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Benecchi 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jessica Federer 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael C. Quirk 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael C. Quirk 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael C. Quirk 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Benecchi 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Barry Greene 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Barrett 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Geno Germano 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregory Shiferman 2025-07-31. Form 4, filed 2025-07-31. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-13. Item 5.07 · say-on-pay result. As reported: 76.72% (votes for as printed: 35,986,261). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-11. Item 5.07 · say-on-pay result. As reported: 95.4% (votes for as printed: 47,705,636). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-16. Item 5.07 · say-on-pay result. As reported: 78.16% (votes for as printed: 39,995,146). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 522,594 + equity 0 + all other 40,000 = 562,594, summed across the director compensation table rows.
- Exelixis, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. View filing ↗
- Halozyme Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in Halozyme Therapeutics, Inc.'s own proxy. As printed: 23,166,223. View filing ↗
- Rhythm Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Rhythm Pharmaceuticals, Inc.'s own proxy. As printed: 17,544,525. View filing ↗
- Supernus Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Supernus Pharmaceuticals, Inc.'s own proxy. As printed: 15,501,557. View filing ↗
- Insmed, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Insmed, Inc.'s own proxy. As printed: 14,467,393. View filing ↗
- Blueprint Medicines Corporation, Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Blueprint Medicines Corporation's own proxy. As printed: 13,477,004. View filing ↗
- BioCryst Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in BioCryst Pharmaceuticals's own proxy. As printed: 12,951,082. View filing ↗
- Mirati Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2023-04-06. CEO total compensation as printed in Mirati Therapeutics, Inc.'s own proxy. As printed: 11,937,371. View filing ↗
- Ultragenyx Pharmaceutical Inc., Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Ultragenyx Pharmaceutical Inc.'s own proxy. As printed: 11,405,535. View filing ↗
- Cerevel Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2023-04-28. CEO total compensation as printed in Cerevel Therapeutics, Inc.'s own proxy. As printed: 11,225,426. View filing ↗
- Apellis Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. View filing ↗
- Axsome Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Axsome Therapeutics, Inc.'s own proxy. As printed: 10,283,492. View filing ↗
- Intra-Cellular Therapies, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-29. CEO total compensation as printed in Intra-Cellular Therapies, Inc.'s own proxy. As printed: 10,086,413. View filing ↗
- Amicus Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. View filing ↗
- Travere Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Travere Therapeutics's own proxy. As printed: 8,457,151. View filing ↗
- Acadia Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Acadia Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. View filing ↗
- Dynavax Technologies, Section 10b CEO total. DEF 14A, filed 2025-04-17. CEO total compensation as printed in Dynavax Technologies's own proxy. As printed: 8,210,775. View filing ↗
- Harmony Biosciences Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Harmony Biosciences Holdings, Inc.'s own proxy. As printed: 7,899,535. View filing ↗
- Ardelyx, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Ardelyx's own proxy. As printed: 7,796,171. View filing ↗
- Crispr Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Crispr Therapeutics, Inc.'s own proxy. As printed: 7,678,477. View filing ↗
- Alector, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 7,492,018. View filing ↗
- Performance, Section 10b CEO total. DEF 14A, filed 2026-10-09. CEO total compensation as printed in Performance's own proxy. As printed: 7,129,941. View filing ↗
- Sage Therapeutics (subject), Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Sage Therapeutics's own proxy. As printed: 7,112,589. View filing ↗
- Tarsus Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Tarsus Pharmaceuticals's own proxy. As printed: 6,617,979. View filing ↗
- Deciphera Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-25. CEO total compensation as printed in Deciphera Pharmaceuticals, Inc.'s own proxy. As printed: 6,010,712. View filing ↗
- Agios Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Agios Pharmaceuticals, Inc.'s own proxy. As printed: 5,370,389. View filing ↗
- Esperion Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Esperion Therapeutics's own proxy. As printed: 3,535,512. View filing ↗
- Amylyx Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Amylyx Pharmaceuticals's own proxy. As printed: 2,719,807. View filing ↗
- Alector, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 1,995,018. View filing ↗
- Ironwood Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Ironwood Pharmaceuticals's own proxy. As printed: 1,948,390. View filing ↗
- Section 10a, Agios Pharmaceuticals, Inc. reciprocity. DEF 14A. Agios Pharmaceuticals, Inc. names Sage Therapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Harmony Biosciences Holdings, Inc. reciprocity. DEF 14A. Harmony Biosciences Holdings, Inc. names Sage Therapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, ACADIA Pharmaceuticals Inc. reciprocity. DEF 14A. ACADIA Pharmaceuticals Inc. names Sage Therapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Cerevel Therapeutics, Inc. reciprocity. DEF 14A. Cerevel Therapeutics, Inc. names Sage Therapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Intra-Cellular Therapies, Inc. reciprocity. DEF 14A. Intra-Cellular Therapies, Inc. names Sage Therapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗